Surgalign Holdings, Inc.
OTCPK:SRGA.Q Rapporto sulle azioni
Cap. di mercato: US$165.3k
Surgalign Holdings Performance dei guadagni passati
Il passato criteri di controllo 0/6 Gli utili di Surgalign Holdings sono diminuiti a un tasso medio annuo di -9.6%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 13.2%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 27.9%.
Informazioni chiave
-9.6%
Tasso di crescita degli utili
0.08%
Tasso di crescita dell'EPS
Medical Equipment Crescita del settore 8.9% Tasso di crescita dei ricavi -27.9% Rendimento del capitale proprio n/a Margine netto -64.6% Ultimo aggiornamento sui guadagni 31 Mar 2023
Aggiornamenti sulle prestazioni recenti
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings: EPS misses analyst expectations Apr 01
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 04
Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 26 Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022
Mostra tutti gli aggiornamenti
Surgalign Holdings, Inc. Files Form 15 Nov 14
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index Jun 23 Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Surgalign Holdings, Inc. Filed for Bankruptcy Jun 20
Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares Jun 12
Price target decreased by 19% to US$2.22 May 18
Consensus estimates of losses per share improve by 87% May 18
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research May 09
Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Consensus revenue estimates fall by 38% Apr 06
Full year 2022 earnings: EPS misses analyst expectations Apr 01
Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System Dec 16 Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million. Nov 17
Price target decreased to US$5.00 Nov 17
Consensus EPS estimates fall by 14% Nov 09
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 04
Price target decreased to US$11.00 Nov 03
Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022 Nov 03
Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 26
Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures Sep 27
Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System Sep 16
Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform Aug 25
Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system Aug 24 Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022
Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue Aug 09
Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary Aug 05
Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission Aug 04
Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 02
Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio Jul 07
Chief Financial Officer recently bought US$100k worth of stock May 20
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12
Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022 May 12
Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System May 06
Price target decreased to US$1.00 Apr 27
Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022 Apr 12
Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022 Apr 08
Consensus forecasts updated Mar 22
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 18 Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer Mar 10
Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System Jan 19
Surgalign Holdings - A Future Of Digital Surgery Dec 21
Price target decreased to US$2.85 Nov 25
Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020) Nov 12
Sizing Up Surgalign Sep 23
Independent Director Jeffrey Lightcap has left the company Sep 17
Chairman Stuart Simpson has left the company Sep 17
Surgalign Holdings: Insiders Are Buying Aug 28
Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation Aug 20
President recently bought US$1.0m worth of stock Aug 14
Surgalign Holdings: Pinocchio Has A Happy Ending Aug 10
Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020) Aug 08
Price target decreased to US$4.21 Aug 07
Surgalign Holdings: A Marketing Ploy Jun 29 Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index
Surgalign reports inducement grants under Nasdaq listing rule Jun 04
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020) May 11
Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System May 11
Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego. May 08
Independent Director has left the company May 08
VP, Chief Accounting Officer & Corporate Controller has left the company May 08
Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019) Mar 18 Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020
Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders Mar 14
Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares? Mar 08
Price target lowered to US$5.00 Mar 08
Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021 Feb 26
Surgalign Holdings, Inc., Annual General Meeting, May 04, 2021 Feb 13
Surgalign Holdings Announces the Commercial Launch of ViBone® Moldable and the First Clinical Implantation Jan 13
Surgalign Holdings : Strong Upside Potential Jan 11
Surgalign Holdings, Inc. Appoints Pawel (Paul) Lewicki to Board of Directors Nov 24
Surgalign Holdings, Inc. and Aziyo Biologics, Inc. Announce Expanded Distribution Agreement Nov 18
Ripartizione dei ricavi e delle spese
Come Surgalign Holdings guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate OTCPK:SRGA.Q Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 31 Mar 23 78 -50 92 14 31 Dec 22 82 -55 96 16 30 Sep 22 83 -62 99 17 30 Jun 22 84 -61 103 16 31 Mar 22 88 -66 104 15 31 Dec 21 91 -81 104 14 30 Sep 21 95 -152 107 11 30 Jun 21 102 -171 107 10 31 Mar 21 98 -185 113 11 31 Dec 20 102 -194 124 12 30 Sep 20 107 -275 137 14 30 Jun 20 108 -266 144 16 31 Mar 20 75 -264 140 17 31 Dec 19 117 -249 135 17 30 Sep 19 157 -49 128 17 30 Jun 19 197 -29 123 16 31 Mar 19 280 -13 123 15 31 Dec 18 92 -52 98 14 30 Sep 18 280 -14 116 13 30 Jun 18 278 0 114 13 31 Mar 18 280 3 114 13 31 Dec 17 280 3 115 13 30 Sep 17 280 -1 116 14 30 Jun 17 280 -22 117 15 31 Mar 17 275 -22 118 16 31 Dec 16 276 -17 117 16 30 Sep 16 278 -3 115 16 30 Jun 16 278 4 111 16 31 Mar 16 282 10 108 16 31 Dec 15 282 12 107 15 30 Sep 15 277 8 108 16 30 Jun 15 276 7 109 16 31 Mar 15 270 6 109 15 31 Dec 14 263 0 108 16 30 Sep 14 252 -9 105 15 30 Jun 14 242 -19 103 16 31 Mar 14 218 -24 91 16 31 Dec 13 198 -19 82 15 30 Sep 13 182 -8 71 14 30 Jun 13 172 4 60 13 31 Mar 13 175 8 59 13 31 Dec 12 178 8 58 12
Guadagni di qualità: SRGA.Q al momento non è redditizia.
Margine di profitto in crescita: SRGA.Q al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: SRGA.Q non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 9.6% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di SRGA.Q nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: SRGA.Q non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Medical Equipment ( 11.7% ).
Rendimento del capitale proprio
ROE elevato: Le passività di SRGA.Q superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio .
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
